Amgenvs.Regeneron
AMGN vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 2.8× larger than Regeneron by market cap; Regeneron trades at the lower P/E (15.7 vs 25.1); year to date, Amgen leads (+11.0% vs −13.9%).
Side by side
| AMGN | REGN | |
|---|---|---|
| Market cap | $196B | $69.7B |
| Price | $363.39 | $664.52 |
| Today | −0.1% | −0.5% |
| Return YTD | +11.0% | −13.9% |
| Return 1Y | +21.0% | +18.7% |
| P/E | 25.1 | 15.7 |
| P/S | 5.3 | 4.7 |
| P/B | 21.3 | 2.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AmgenAMGN
Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.
Full AMGN profile →RegeneronREGN
American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.
Full REGN profile →More comparisons in Biotech & innovation
See where AMGN and REGN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →